Does trimethoprim-sulfamethoxazole prophylaxis for HIV induce bacterial resistance to other antibiotic classes?: Results of a systematic review

Clinical Infectious Diseases

Volumn 52, Issue 9, 2011, Pages 1184-1194

  Sibanda, Euphemia L ^a,b   Weller, Ian V D ^b   Hakim, James G ^a   Cowan, Frances M ^a,b  

^a UNIVERSITY OF ZIMBABWE   (Zimbabwe)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; CEFAZOLIN; CEFOTAXIME; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; ERYTHROMYCIN; GENTAMICIN; PENICILLIN G; RIFAMPICIN; TETRACYCLINE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; CD4 LYMPHOCYTE COUNT; COMMUNICABLE DISEASE; HAEMOPHILUS INFLUENZAE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOCOMPROMISED PATIENT; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORAXELLA CATARRHALIS; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; SKIN INFECTION; STREPTOCOCCUS PNEUMONIAE; SYSTEMATIC REVIEW; VANCOMYCIN RESISTANT ENTEROCOCCUS;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-BACTERIAL AGENTS; ANTIBIOTIC PROPHYLAXIS; BACTERIA; BACTERIAL INFECTIONS; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DRUG RESISTANCE, BACTERIAL; FEMALE; HIV INFECTIONS; HUMANS; TRIMETHOPRIM-SULFAMETHOXAZOLE COMBINATION;

EID: 79953853917     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cir067     Document Type: Article

References (38)

1. Anglaret X, Chene G, Attia A, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Cote d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet 1999; 353:1463-8. (Pubitemid 29204363)
2. Wiktor SZ, Sassan-Morokro M, Grant AD, et al. Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353: 1469-75. (Pubitemid 29204364)
3. Chintu C, Bhat GJ, Walker AS, et al. Cotrimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet 2004; 364:1865-71. (Pubitemid 39536090)
4. Walker AS, Ford D, Gilks CF, et al. Daily cotrimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 2010; 375:1278-1286.
5. World Health Organisation. Provisional WHO/UNAIDS Secretariat recommendations on the use of cotrimoxazole prophylaxis in adults and children living with HIV/AIDS in Africa. Geneva, Switzerland: WHO/UNAIDS, 2000.
6. World Health Organisation. Guidelines on cotrimoxazole prophylaxis for HIV related infections among chidren, adolescents and adults: recommendations for a public health approach. Switzerland: WHO, 2006.
7. Zachariah R, Harries AD, Luo C, Bachman G, Graham SM. Scaling-up cotrimoxazole prophylaxis in HIV-exposed and HIV-infected children in high HIV-prevalence countries. Lancet Infect Dis 2007; 7:686-93. (Pubitemid 47454563)
8. World Health Organisation. Taking Stock: HIV in children. Geneva: Word Helath Organisation, 2006.
9. Zimbabwe Ministry of Health and Child Welfare. Zimbabwe Ministry of Health and Child Welfare: HIV Estimates Report 2007. Estimates Reports. Harare: Government of Zimbabwe, 2008.
10. Ryan M, Griffin S, Chitah B, et al. The cost-effectiveness of cotrimoxazole prophylaxis in HIV-infected children in Zambia. AIDS 2008; 22:749-57. (Pubitemid 351450644)
11. Yazdanpanah Y, Losina E, Anglaret X, et al. Clinical impact and cost-effectiveness of cotrimoxazole prophylaxis in patients with HIV/AIDS in Cote d'Ivoire: a trial-based analysis. AIDS 2005; 19:1299-308. (Pubitemid 41224899)
12. Badri M, Ehrlich R, Wood R, Maartens G. Initiating cotrimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 2001; 15:1143-8. (Pubitemid 32549865)
13. Nunn AJ, Mwaba P, Chintu C, Mwinga A, Darbyshire JH, Zumla A. Role of cotrimoxazole prophylaxis in reducing mortality in HIV infected adults being treated for tuberculosis: randomised clinical trial. BMJ 2008; 337:a257. http://www.bmj.com/content/337/bmj.a257.long. Accessed 2 February 2011.
14. Thera MA, Sehdev PS, Coulibaly D, et al. Impact of trimethoprim- sulfemethoxazole prophylaxis on falciparum malaria infection and disease. J Infect Dis 2005; 192:1823-9. (Pubitemid 41587836)
15. Gill CJ, Sabin LL, Tham J, Hamer DH. Reconsidering empirical cotrimoxazole prophylaxis for infants exposed to HIV infection. Bull World Health Organ 2004; 82:290-7. (Pubitemid 38568466)
16. Hamel MJ, Greene C, Chiller T, et al. Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 2008; 79:320-30.
17. Gill CJ, Mwanakasale V, Fox MP, et al. Effect of presumptive cotrimoxazole prophylaxis on pneumococcal colonization rates, seroepi-demiology and antibiotic resistance in Zambian infants: a longitudinal cohort study. Bull World Health Organ 2008; 86:929-38.
18. National Institute for Health and Clinical Excellence (NICE). NICE: Guideline Development Methods (Appendices): D Methodology checklist: cohort studies Available at:http://www.nice.org.uk/pdf/GDM-AppedixD.pdf. Accessed 11 April 2009.
19. National Institute for Health and Clinical Excellence (NICE). NICE: Guideline Development Methods (Appendices): E Methodology checklist: casecontrol studies Available at: http://www.nice.org.uk/pdf/GDM-AppendixE.pdf. Accessed 11 April 2009.
20. Crum-Cianflone NF, Burgi AA, Hale BR. Increasing rates of community-acquired methicillin-resistant Staphylococcus aureus infections among HIV-infected persons. Int J STD AIDS 2007; 18:521-26. (Pubitemid 351738938)
21. Jordano Q, Falco V, Almirante B, et al. Invasive pneumococcal disease in patients infected with HIV: still a threat in the era of highly active antiretroviral therapy. Clin Infect Dis 2004; 38:1623-8. (Pubitemid 38738561)
22. Madhi SA, Petersen K, Madhi A, Wasas A, Klugman KP. Impact of human immunodeficiency virus type 1 on the disease spectrum of Streptococcus pneumoniae in South African children. Pediatr Infect Dis J 2000; 19:1141-7. (Pubitemid 32003356)
23. Mathews WC, Caperna JC, Barber RE, et al. Incidence of and risk factors for clinically significant methicillin-resistant Staphylococcus aureus infection in a cohort of HIV-infected adults. Acquir Immune Defic Syndr 2005; 40:155-60. (Pubitemid 41395713)
24. Drapeau CMJ, Angeletti C, Festa A, Petrosillo N. Role of previous hos-pitalization in clinically-significant MRSA infection among HIV-infected inpatients: results of a casecontrol study. Infect Dis 2007; 7:36: (http://www.biomedcentral.com/1471-2334/7/36. Accessed 4 February 2011) BMC.
25. Lee NE, Taylor MM, Bancroft E, et al. Risk factors for community-associated methicillin-resistant Staphylococcus aureus skin infections among HIV-positive men who have sex with men. Clin Infect Dis 2005; 40:1529-34. (Pubitemid 40628644)
26. Meynard JL, Barbut F, Blum L, et al. Risk factors for isolation of Streptococcus pneumoniae with decreased susceptibility to penicillin G from patients infected with human immunodeficiency virus. Clin Infect Dis 1996; 22:437-40. (Pubitemid 26259171)
27. Tumbarello M, de Gaetano Donati K, Tacconelli E, et al. Risk factors and predictors of mortality of methicillin-resistant Staphylococcus aureus (MRSA) bacteraemia in HIV-infected patients. J Antimicrob Chemother 2002; 50:375-82.
28. Achenbach C, Flores E, Ferrell P, Pitrak D, Weber SG. Prevalence of and risk factors for colonization with vancomycin-resistant entero-coccus among human immunodeficiency virus-positive outpatients. Infect Control Hosp Epidemiol 2006; 27:102-4. (Pubitemid 46939766)
29. Cenizal MJ, Hardy RD, Anderson M, Katz K, Skiest DJ. Prevalence of and risk factors for methicillin-resistant Staphylococcus aureus (MRSA) nasal colonization in HIV-infected ambulatory patients. J Acquir Immune Defic Syndr 2008; 48:567-71.
30. Cotton MF, Wasserman E, Smit J, Whitelaw A, Zar HJ. High incidence of antimicrobial resistant organisms including extended spectrum beta-lactamase producing enterobacteriaceae and methicillin-resistant Staphylococcus aureus in nasopharyngeal and blood isolates of HIV-infected children from Cape Town, South Africa. BMC Infect Dis 2008; 8:40: (http://www.biomedcentral.com/1471-2334/8/ 40). Accessed 4 February 2011.
31. Villacian JS, Barkham T, Earnest A, Paton NI. Prevalence of and risk factors for nasal colonization with Staphylococcus aureus among human immunodeficiency virus-positive outpatients in Singapore. Infect Control Hosp Epidemiol 2004; 25:438-40. (Pubitemid 38621094)
32. Zar HJ, Hanslo D, Hussey G. The impact of HIV infection and trimethoprim-sulphamethoxazole prophylaxis on bacterial isolates from children with community-acquired pneumonia in South Africa. Trop Pediatr 2003; 49:78-83. (Pubitemid 36503733)
33. Pemba L, Charalambous S, von Gottberg A, et al. Impact of cotrimoxazole on non-susceptibility to antibiotics in Streptococcus pneumoniae carriage isolates among HIV-infected mineworkers in South Africa. J Infect 2008; 56:171-8.
34. Martin JN, Rose DA, Hadley WK, Perdreau-Remington F, Lam PK, Gerberding JL. Emergence of trimethoprim-sulfamethoxazole resistance in the AIDS era. J Infect Dis 1999; 180:1809-18.
35. Marinda E, Humphrey JH, Iliff PJ, et al. Child mortality according to maternal and infant HIV status in Zimbabwe. Pediatr Infect Dis J 2007; 26:519-26. (Pubitemid 46847314)
36. McNally LM, Jeena PM, Gajee K, et al. Effect of age, polymicrobial disease, and maternal HIV status on treatment response and cause of severe pneumonia in South African children: a prospective descriptive study. Lancet 2007; 369:1440-51. (Pubitemid 46635781)
37. Teuber M, Meile L, Schwarz F. Acquired antibiotic resistance in lactic acid bacteria from food. ntonie Van Leeuwenhoek 1999; 76:115-37.
38. Hidron AI, Kourbatova EV, Halvosa JS, et al. Risk factors for colonization with methicillin-resistant Staphylococcus aureus (MRSA) in patients admitted to an urban hospital: emergence of community-associated MRSA nasal carriage. Clin Infect Dis 2005; 41:159-66. (Pubitemid 40962495)